Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02443402 · ClinicalTrials.gov registry record · Phase 4
Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 68
- Enrollment target
NCT02443402 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 68 participants.
The verdict
NCT02443402, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 68 participants
- Enrollment target
Study Summary
The purpose of this study is to compare sitagliptin and placebo for the prevention of high blood glucose during surgery.
Interventions
- DRUG Placebo
- DRUG Sitagliptin
- DRUG Insulin glargine
- DRUG Regular Human Insulin
- DRUG Supplemental insulin (Insulin lispro)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2016-01 |
| Est. Completion | 2016-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02443402
The ClinicalTrials.gov registry entry for NCT02443402 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02443402 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02443402 about?
NCT02443402 is a clinical study titled "Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery". The purpose of this study is to compare sitagliptin and placebo for the prevention of high blood glucose during surgery.
What is the current status of trial NCT02443402?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 68 participants. The study started on 2016-01. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02443402?
The interventions under investigation include: Placebo (DRUG), Sitagliptin (DRUG), Insulin glargine (DRUG), Regular Human Insulin (DRUG), Supplemental insulin (Insulin lispro) (DRUG).
Who is sponsoring clinical trial NCT02443402?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.